意大利近二十年HIV耐药流行率大幅下降但多药耐药仍需关注
该研究评估了意大利1999—2018年接受抗逆转录病毒治疗(ART)失败的HIV-1感染者分离株的耐药流行率及治疗相关性。对至少一类药物耐药的比例从≤2001年的84.6%降至2010年的43.6%(P<0.001),2010—2018年稳定在约40%,对三类及以上药物耐药的比例稳定在约5%。在1827例治疗失败且有随访的患者中,基因型指导治疗后1年病毒学成功(VS)概率为87.6%,但三类及以上累计耐药且接受低活性方案者VS概率最低(62.6%)。
要点
- 意大利HIV-1失败株对至少一类药物耐药从84.6%降至约40%后趋稳,三类及以上耐药约5%。
- 三类及以上累计耐药且接受低活性方案者1年病毒学成功概率最低(62.6%)。
- 多药耐药(MDR)仍存在,需合理的诊断与治疗管理策略。
核心结论
- 意大利近二十年HIV-1治疗失败株耐药大幅下降,但对三类及以上药物耐药仍低水平存在,MDR管理仍需理性、细致的诊断与治疗策略。
研究设计与样本
- 回顾性分析意大利1999—2018年ART经治HIV-1感染者分离株的耐药动态。
- 评估对一、二、三类及以上药物类别的耐药,并按累计类别耐药与累计基因型敏感评分(Stanford HIV_DB算法)评估最新换药后的病毒学成功。
主要发现
- 对至少一类药物耐药从≤2001年的84.6%降至2010年的43.6%(P<0.001),2010—2018年维持在约40%。
- 对三类及以上药物耐药比例稳定在约5%。
- 2008年后整合酶抑制剂耐药从5.6%升至2018年的9.7%,在三类及以上耐药株中占34.7%(P<0.001)。
- 1827例失败且有随访患者中,基因型指导治疗开始后1年VS概率为87.6%。
- 三类及以上累计耐药且接受低活性方案者VS概率为62.6%(P<0.001),其他患者≥81.8%。
关键数值与推荐
- 对至少一类药物耐药:≤2001年84.6%,2010年43.6%,2010—2018年约40%。
- 对三类及以上药物耐药:约5%。
- 整合酶抑制剂耐药:2008年5.6%升至2018年9.7%;在三类及以上耐药株中为34.7%。
- 1年VS概率:总体87.6%;三类及以上耐药且低活性方案62.6%;其他患者≥81.8%。
临床怎么用
- 对ART失败者应结合累计耐药史与基因型敏感评分选择活性方案。
- 三类及以上累计耐药且方案活性不足者病毒学成功概率低,需更审慎的换药与管理。
局限性
- 为意大利单国数据,外推需谨慎。
- 部分分析基于可获得随访的失败患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the prevalence and therapeutic relevance of drug resistance among isolates from ART-experienced HIV-1-infected patients over the past two decades in Italy. METHODS: Dynamics of resistance to one, two and three or more antiretroviral classes were evaluated from 1999-2018. Virological success (VS) after the latest therapy switch was evaluated according to cumulative class resistance and cumulative genotypic susceptibility score (Stanford HIV_DB algorithm). RESULTS: Among 13 663 isolates (from 6739 patients), resistance to at least one drug class decreased sharply from 1999 to 2010 (≤2001, 84.6%; 2010, 43.6%; P < 0.001), then remained relatively constant at ∼40% during 2010-18, with the proportion of resistance to three or more classes also stable (∼5%). After 2008, integrase inhibitor resistance slightly increased from 5.6% to 9.7% in 2018 and contributed to resistance, particularly in isolates with resistance to three or more classes (one class, 8.4%; two classes, 15.3%; three or more classes, 34.7%, P < 0.001). Among 1827 failing patients with an available follow-up, by 1 year after genotype-guided therapy start the probability of VS was 87.6%. Patients with cumulative resistance to three or more classes and receiving a poorly active regimen showed the lowest probability (62.6%) of VS (P < 0.001) compared with all other patients (≥81.8%). By Cox regression analysis, cumulative MDR and receiving poorly active antiretroviral regimens were associated with a lower hazard of VS compared with those without resistance. CONCLUSIONS: A dramatic drop of HIV-1 drug resistance at failure has been achieved over the last two decades in Italy; resistance to three or more classes is low but present among currently failing patients. Its management still requires a rational and careful diagnostic and therapeutic approach.
引用
- Armenia D, Di Carlo D, Flandre P, et al. HIV MDR is still a relevant issue despite its dramatic drop over the years. J Antimicrob Chemother. 2020. PMID: 31976521. doi:10.1093/jac/dkz554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。